TTI-0102

DRUG4 trials

Sponsors

Thiogenesis Therapeutics, VA Office of Research and Development, Thiogenesis Therapeutics, Inc.

Conditions

COVID-19COVID-19 Acute Respiratory Distress SyndromeMELAS SyndromeMild to Moderate TBIMitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)Mitochondrial encephalomyopathyPosttraumatic Stress Disorderlactic acidosis and stroke-like episodes (MELAS)

Phase 1

TTI-0102 for Veterans With TBI

WithdrawnNCT04262895

VA Office of Research and DevelopmentMild to Moderate TBI, Posttraumatic Stress Disorder

Start: 2021-10-01End: 2021-10-15Updated: 2021-10-26

Phase 2

Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

WithdrawnNCT05212662

Thiogenesis Therapeutics, Inc.COVID-19, COVID-19 Acute Respiratory Distress Syndrome

Start: 2024-09-27End: 2024-09-27Updated: 2024-10-01

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

CompletedNCT06644534

Thiogenesis Therapeutics, Inc.MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

Start: 2025-05-12End: 2026-01-12Updated: 2026-07-24

A Multi-Center, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral TTI-0102 for Treatment of Patients with Mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS).

CompletedCTIS2023-506723-28-00

Thiogenesis Therapeuticslactic acidosis and stroke-like episodes (MELAS), Mitochondrial encephalomyopathy

Start: 2025-03-20End: 2026-01-12Target: 12Updated: 2025-09-22